Sort
85,873 grants matching “alzheimers”
ARIC Neurocognitive Study (ARIC-NCS) Renewal
$9,888,004Josef Coresh · Johns Hopkins University · U01 · FY2019 · HL
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
$9,845,298Paul S. Aisen · University Of Southern California · R01 · FY2020 · AG
Data Collection, Linkages, Cleaning and Sharing Core
$9,841,539James R Wagner · University Of Michigan At Ann Arbor · U54 · FY2025 · AG
IU/JAX/PITT MODEL-AD Center
$9,833,325Bruce T Lamb · Indiana University Indianapolis · U54 · FY2025 · AG
IU/JAX/PITT MODEL-AD Center
$9,833,325Bruce T Lamb · Indiana University Indianapolis · U54 · FY2023 · AG
IU/JAX/PITT MODEL-AD Center
$9,833,325Bruce T Lamb · Indiana University Indianapolis · U54 · FY2024 · AG
IU/JAX/PITT MODEL-AD Center
$9,790,785Bruce T Lamb · Indiana University Indianapolis · U54 · FY2022 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
$9,769,679Paul S. Aisen · University Of Southern California · R01 · FY2021 · AG
Education and Cognitive Functioning in Later Life: The Nationâs High School Class of 1972
$9,675,645Chandra L Muller · University Of Texas At Austin · R01 · FY2023 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$9,664,204Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2022 · AG
Alzheimer's Disease Cooperative Study (ADCS)
$9,638,092Paul S. Aisen · University Of California, San Diego · U01 · FY2009 · AG
Metformin in Alzheimer's dementia Prevention (MAP)
$9,597,463Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2021 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$9,592,233Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2025 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease
$9,590,782Ed Lein · Allen Institute · U19 · FY2022 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease
$9,555,451Ed Lein · Allen Institute · U19 · FY2023 · AG
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
$9,503,062Charles Decarli · University Of California At Davis · U19 · FY2023 · NS
PREVENTABLE Clinical Sites Core
$9,500,414Adrian Hernandez · Duke University · U19 · FY2023 · AG
Alzheimer's Disease Neuroimaging Initiative
$9,498,081Michael W Weiner · Northern California Institute/Res/Edu · U01 · FY2008 · AG
Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL)
$9,466,491Katie L Stone · California Pacific Med Ctr Res Institute · RF1 · FY2025 · AG
Advancing the Science of Palliative Care Research Across the Lifespan (ASCENT) Consortium
$9,464,050Jean S Kutner · University Of Colorado Denver · U54 · FY2025 · AG
ASPirin in Reducing Events in the Elderly - eXTension
$9,454,419Anne M Murray · Hennepin Healthcare Research Institute · U19 · FY2019 · AG
DIAN Administrative Core
$9,449,620John Morris · Washington University · UF1 · FY2014 · AG
Johns Hopkins Institute for Clinical and Translational Research
$9,447,408Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2022 · TR
Center for Alzheimer's and Related Dementias (CARD): iPSC Neurodegenerative Diseases Initiative
$9,416,906Andrew Singleton · National Institute On Aging · ZIA · FY2022 · AG
Center for Alzheimer's and Related Dementias (CARD): iPSC Neurodegenerative Diseases Initiative
$9,379,957Andrew Singleton · National Institute On Aging · ZIA · FY2023 · AG